Search
Menu
Zurich Instruments AG - Boost Your Optics 1-24 LB

CIBA Vision, British Firm to Partner on Photodynamic Therapy

Facebook X LinkedIn Email
DULUTH, Ga., Dec. 1 -- The CIBA Vision unit of Novartis has signed a co-development agreement with Destiny Pharma of Brighton, England, that grants CIBA Vision exclusive worldwide rights to develop Destiny Pharma's photodynamic therapy technology for the treatment of ophthalmic diseases. The agreement calls for CIBA Vision to pay a series of milestone payments and royalties to Destiny Pharma, and to take control of development upon completion of the current research program. Destiny Pharma will retain all rights to the technology platform for other disease indications. The technology resulted...Read full article

Related content from Photonics Media



    Photonics Handbook Articles


    Webinars
    Published: December 1999
    Basic ScienceNews & Features

    We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.